Belite Bio, Inc (BLTE)
BLTE Stock Price Chart
Explore Belite Bio, Inc interactive price chart. Choose custom timeframes to analyze BLTE price movements and trends.
BLTE Company Profile
Discover essential business fundamentals and corporate details for Belite Bio, Inc (BLTE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Apr 2022
Employees
25.00
Website
https://belitebio.comCEO
Yu-Hsin Lin
Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Financial Timeline
Browse a chronological timeline of Belite Bio, Inc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.54.
Earnings released on 11 Aug 2025
EPS came in at -$0.50 falling short of the estimated -$0.47 by -6.38%.
Earnings released on 13 May 2025
EPS came in at -$0.45 falling short of the estimated -$0.36 by -25.00%.
Earnings released on 17 Mar 2025
EPS came in at -$0.32 falling short of the estimated -$0.30 by -6.67%.
Earnings released on 12 Nov 2024
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%.
Earnings released on 9 Aug 2024
EPS came in at -$0.31 falling short of the estimated -$0.28 by -10.71%.
Earnings released on 13 May 2024
EPS came in at -$0.27 surpassing the estimated -$0.34 by +20.59%.
Earnings released on 11 Mar 2024
EPS came in at -$0.25 surpassing the estimated -$0.36 by +30.56%.
Earnings released on 13 Nov 2023
EPS came in at -$0.40 falling short of the estimated -$0.31 by -29.03%.
Earnings released on 8 Aug 2023
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%.
Earnings released on 10 May 2023
EPS came in at -$0.33 falling short of the estimated -$0.20 by -65.00%.
Earnings released on 31 Mar 2023
EPS came in at -$1.04 falling short of the estimated -$0.22 by -374.41%.
Earnings released on 30 Sept 2022
EPS came in at -$0.10 .
Earnings released on 10 Aug 2022
EPS came in at -$0.12 surpassing the estimated -$0.23 by +49.67%.
Earnings released on 29 Apr 2022
EPS came in at -$0.26 .
Earnings released on 31 Mar 2022
EPS came in at -$0.05 .
Earnings released on 30 Sept 2021
EPS came in at -$0.26 .
Earnings released on 30 Jun 2021
EPS came in at -$0.25 .
Earnings released on 31 Mar 2021
EPS came in at -$0.25 .
Earnings released on 31 Dec 2020
EPS came in at -$0.21 .
Earnings released on 30 Sept 2020
EPS came in at -$0.21 .
BLTE Stock Performance
Access detailed BLTE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.